<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146202">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01783886</url>
  </required_header>
  <id_info>
    <org_study_id>15161</org_study_id>
    <nct_id>NCT01783886</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement</brief_title>
  <acronym>VIVID EAST</acronym>
  <official_title>A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap Eye in Subjects With Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <authority>Hong Kong: Department of Health</authority>
    <authority>Russia: Federal Service on Surveillance in Healthcare</authority>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy of intravitreally (IVT) administered VEGF Trap-Eye on the
      best-corrected visual acuity (BCVA) assessed by the early treatment diabetic retinopathy
      study (ETDRS) chart in subjects with diabetic macular edema (DME) with central involvement.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in best-corrected visual acuity (BCVA) in ETDRS (Early Treatment Diabetic Retinopathy Study) letter score</measure>
    <time_frame>From baseline to week 52</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in retinal thickness</measure>
    <time_frame>From baseline to week 52</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who gain a threshold change in visual acuity</measure>
    <time_frame>From baseline to week 52</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) near activities subscale</measure>
    <time_frame>From baseline to week 52</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) distance activities subscale</measure>
    <time_frame>From baseline to week 52</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">375</enrollment>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>VEGF Trap-Eye Regimen 1 + Laser photocoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VEGF Trap-Eye Regimen 1. Additional treatment with macular laser photocoagulation possible if criteria are met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VEGF Trap-Eye Regimen 2 + Laser photocoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VEGF Trap-Eye Regimen 2. Additional treatment with macular laser photocoagulation possible if criteria are met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laser photocoagulation + VEGF Trap-Eye</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Macular laser photocoagulation using modified ETDRS protocol. Additional treatment with VEGF Trap-Eye possible if criteria are met.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)</intervention_name>
    <arm_group_label>VEGF Trap-Eye Regimen 1 + Laser photocoagulation</arm_group_label>
    <arm_group_label>VEGF Trap-Eye Regimen 2 + Laser photocoagulation</arm_group_label>
    <arm_group_label>Laser photocoagulation + VEGF Trap-Eye</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laser photocoagulation</intervention_name>
    <arm_group_label>VEGF Trap-Eye Regimen 1 + Laser photocoagulation</arm_group_label>
    <arm_group_label>VEGF Trap-Eye Regimen 2 + Laser photocoagulation</arm_group_label>
    <arm_group_label>Laser photocoagulation + VEGF Trap-Eye</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults â‰¥ 18 years with type 1 or 2 diabetes mellitus

          -  Subjects with diabetic macular edema (DME) secondary to diabetes mellitus involving
             the center of the macula in the study eye

          -  Decrease in vision determined to be primarily the result of DME in the study eye

          -  Best-corrected visual acuity (BCVA) early treatment diabetic retinopathy study
             (ETDRS) letter score of 73 to 24 (20/40 to 20/320) in the study eye

        Exclusion Criteria:

          -  Laser photocoagulation (panretinal or macular) in the study eye within 90 days of Day
             1

          -  More than 2 previous macular laser treatments in the study eye

          -  Previous use of intraocular or periocular corticosteroids in the study eye within 120
             days of Day 1

          -  Previous treatment with antiangiogenic drugs in either eye (pegaptanib sodium,
             bevacizumab, ranibizumab etc.) within 90 days of Day 1

          -  Active proliferative diabetic retinopathy (PDR) in the study eye

          -  Uncontrolled diabetes mellitus, as defined by HbA1c &gt;12%

          -  Only 1 functional eye even if that eye is otherwise eligible for the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <email>clinical-trials-contact@bayerhealthcare.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510064</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100083</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>2000080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chongqing</city>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>127486</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>10506</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Novosibirsk</city>
        <zip>630071</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>February 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Macular Edema</keyword>
  <keyword>DME</keyword>
  <keyword>VEGF Trap-Eye</keyword>
  <keyword>best-corrected visual acuity (BCVA)</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
